ジェイファーマ
520A・Growth Market・Pharmaceuticals
ジェイファーマ
520A・Growth Market・Pharmaceuticals
J Pharma (single segment)
A global drug discovery venture's single business segment centered on LAT1 inhibitors
| Period | Current | Previous | Change |
|---|---|---|---|
| Operating loss | -¥3,710 million | -¥1,596 million | ↓ |
| Ordinary loss | -¥2,636 million | -¥1,527 million | ↓ |
| Net loss | -¥2,466 million | -¥1,499 million | ↓ |
| Total assets | ¥4,761 million | ¥2,857 million | ↑ |
| Cash and cash equivalents balance | ¥4,453 million | ¥2,302 million | ↑ |
Business Details
Specializes in small-molecule drug discovery targeting LAT1 (L-type amino acid transporter 1), a type of SLC transporter. The lead compound Nanvuranlat (JPH203) is undergoing a global Phase 3 clinical trial primarily for biliary tract cancer. The second compound, JPH034, has begun a U.S. Phase 1 clinical trial for non-relapsing secondary progressive multiple sclerosis. The company has not yet recorded revenue and is a development-stage company with research and development expenses preceding revenue. It aims to generate revenue through global licensing agreements.
Recent Overview
Key progress includes the start of the global Phase 3 trial and the start of JPH034's U.S. Phase 1 trial
Initiated the global Phase 3 clinical trial (Beacon-BTC) for Nanvuranlat in December 2025, progressing as planned as of June 2026. On March 22, 2026, initiated the U.S. Phase 1 clinical trial for JPH034, with dosing of the first subject completed. Presented a poster on subgroup and exposure-response analyses of the Nanvuranlat Phase 2 trial at ESMO 2025 in October 2025. In Japan, an investigator-initiated trial (JON-2404-B) of first-line ICI combination therapy for biliary tract cancer was registered and published in jRCT in April 2026. On the financial side, the company raised ¥3,777 million through third-party allotment and public offerings, significantly increasing its cash balance, while operating loss expanded by ¥2,114 million year-on-year due to increased clinical trial expenses.
Key Products
Growth Drivers
- Steady progress of Nanvuranlat's global Phase 3 clinical trial (Beacon-BTC) and the potential for a future global licensing agreement
- High unmet medical need among the approximately 70% of biliary tract cancer second-line patients for whom no approved drug currently exists
- Entry into the non-relapsing secondary progressive multiple sclerosis market (estimated at approximately $5.6 billion in 2024, projected to reach approximately $9.8 billion by 2033) via JPH034
- Lifecycle management through expansion of Nanvuranlat's indications to first-line ICI combination therapy, KRAS-mutant colorectal cancer, and rare diseases
- Strengthened financial base (cash balance of ¥4,453 million) through third-party allotments and public offerings, securing continued capacity for R&D investment
Risks
- No business revenue has been recorded, and operating loss has expanded (up approximately ¥2,114 million year-on-year) due to rising clinical trial costs, requiring continued fundraising
- Risk that failure of the global Phase 3 clinical trial to achieve its primary endpoint would make it difficult to build a commercialization scheme
- Risk that licensing negotiations, which depend on the judgment of counterpart companies, could delay the establishment of a commercialization scheme beyond FY2028 (ending March 2028)
- Regulatory approval uncertainty in the same therapeutic area, as exemplified by competing products (such as the BTK inhibitor tirabrutinib) receiving a CRL from the FDA
- Uncertainty stemming from fluctuations in U.S. tariff policy and drug pricing policy affecting the investment environment for the pharmaceutical industry as a whole
Last updated: June 24, 2026